ArticleBJU international2026
Assessment of new prognostic risk models for recurrence in patients with clinical stage I seminoma.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate two new prognostic risk models aimed at improving clinical decision-making in patients with clinical stage (cS) I seminomatous testicular germ cell tumours (GCTs), 5%-30% of whom experience recurrence during surveillance after orchiectomy and may benefit from adjuvant therapy.
methodsIn this exploratory study, patients with unilateral cS I seminoma, normalised serum tumour markers after orchiectomy, no adjuvant therapy and at least 12 months of follow-up were included. Cox regression analysis was applied to evaluate the prognostic factors proposed by the Danish Testicular Cancer Database (DaTeCa) and the European Association of Urology (EAU), and recurrence probabilities were estimated using the Kaplan-Meier method.
resultsAmong 139 patients, 25 (18%) experienced recurrence within a median follow-up of 37 months (95% confidence interval 47.9-63.1 months). Multivariable analysis confirmed only rete testis infiltration as an independent predictor of recurrence (P = 0.039), while other prognostic factors included in the DaTeCa risk model (i.e. hilar soft tissue invasion, rete testis infiltration, lymphovascular invasion, and elevated pre-orchiectomy human chorionic gonadotropin and lactate dehydrogenase) and the EAU model (i.e. tumour size, rete testis infiltration and lymphovascular invasion) were not. However, 5-year recurrence risks for the different risk groups, defined by the combination of prognostic factors, aligned well with the DaTeCa (no risk factors: 4% vs 6%; all risk factors: 67% vs 62%) and the EAU risk models (low [13% vs 8%] and intermediate risk [22% vs 20%]). A discrepancy was observed in EAU high-risk cases (67% vs 44%), which was probably attributable to the very small number of patients in our high-risk subgroup (n = 6 [4.3%]).
conclusionThe DaTeCa and EAU risk classification models demonstrated overall consistency in our exploratory cohort and may aid in identifying patients with cS I seminoma who are at high risk for recurrence and who might be candidates for adjuvant therapy. Further multicentre validation studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.